Skip to main content

NASDAQ:ROSG - (ROSG) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.43
+0.30 (1.20%)
Get New (ROSG) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ROSG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ROSG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (ROSG) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.43.

N/A

The current consensus among 0 investment analysts is to n/a stock in (ROSG). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/27/2018S&P Equity ResearchLower Price Target$0.03 ➝ $0.02N/A
i
7/6/2018S&P Equity ResearchBoost Price TargetN/A
i
12/18/2017Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
1/6/2017AegisReiterated RatingBuy$3.50N/A
i
9/7/2016S&P Equity ResearchLower Price Target$0.94 ➝ $0.82N/A
i
6/13/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
5/26/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
(Data available from 5/16/2016 forward)
(ROSG) logo
Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The company develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers proprietary microRNA technologies, such as Rosetta Cancer Origin, mi-KIDNEY, and RosettaGX Reveal Test. The company was founded by Isaac Bentwich on March 9, 2000 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $0.43
$0.42
$0.44

50 Day Range

MA: $0.43
$0.43
$0.43

52 Week Range

Now: $0.43
$0.23
$2.75

Volume

169,599 shs

Average Volume

81,512 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (ROSG)?

The following Wall Street analysts have issued reports on (ROSG) in the last twelve months:
View the latest analyst ratings for ROSG.

What is the current price target for (ROSG)?

0 Wall Street analysts have set twelve-month price targets for (ROSG) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (ROSG) in the next year.
View the latest price targets for ROSG.

What is the current consensus analyst rating for (ROSG)?

(ROSG) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ROSG.

What other companies compete with (ROSG)?

How do I contact (ROSG)'s investor relations team?

(ROSG)'s physical mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company's listed phone number is 972732220700 and its investor relations email address is [email protected] The official website for (ROSG) is www.rosettagenomics.com.